Concarlo Therapeutics
Concarlo Therapeutics is developing first-in-class inhibitors of p27, the master regulator of CDK2/4/6, to address drug resitant cancers.
Concarlo Therapeutics is developing first-in-class inhibitors of p27, the master regulator of CDK2/4/6, to address drug resitant cancers.